(Q38001410)

26 August 2017

title

An update on advanced glycation endproducts and atherosclerosis (English)

1 reference

26 August 2017

1 reference

Serena Del Turco

1

0 references

Giuseppina Basta

object named as

Giuseppina Basta

series ordinal

2

0 references

publication date

10 April 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

38

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

266-274

1 reference

Biochemistry and molecular cell biology of diabetic complications

26 August 2017

cites work

1 reference

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study

21 January 2018

1 reference

Oxidative Stress and Diabetic Complications

21 January 2018

1 reference

A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease

21 January 2018

1 reference

Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies

21 January 2018

1 reference

N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression

21 January 2018

1 reference

Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications.

21 January 2018

1 reference

The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease

21 January 2018

1 reference

Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury

21 January 2018

1 reference

Mechanisms for oxidative stress in diabetic cardiovascular disease

21 January 2018

1 reference

Aldose reductase and AGE-RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats.

21 January 2018

1 reference

The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation

21 January 2018

1 reference

Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products

21 January 2018

1 reference

Advanced glycoxidation end products in commonly consumed foods

21 January 2018

1 reference

Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy

21 January 2018

1 reference

The role of advanced glycation end products in the development of atherosclerosis

21 January 2018

1 reference

Advanced glycation end products: sparking the development of diabetic vascular injury

21 January 2018

1 reference

RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts

21 January 2018

1 reference

At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products

21 January 2018

1 reference

RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides

21 January 2018

1 reference

Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of dia

21 January 2018

1 reference

Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: relevance to diabetes

21 January 2018

1 reference

Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway

21 January 2018

1 reference

Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury

21 January 2018

1 reference

beta(2)-Microglobulin modified with advanced glycation end products delays monocyte apoptosis

21 January 2018

1 reference

Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications

21 January 2018

1 reference

Glycated LDL increases monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated chemotaxis

21 January 2018

1 reference

Regulation of Src homology 2-containing protein tyrosine phosphatase by advanced glycation end products: the role on atherosclerosis in diabetes

21 January 2018

1 reference

Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model

21 January 2018

1 reference

Monocyte-endothelium-smooth muscle cell interaction in co-culture: proliferation and cytokine productions in response to advanced glycation end products.

21 January 2018

1 reference

Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts

21 January 2018

1 reference

RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice.

21 January 2018

1 reference

RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes

21 January 2018

1 reference

Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes

21 January 2018

1 reference

Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study

21 January 2018

1 reference

The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control

21 January 2018

1 reference

Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes

21 January 2018

1 reference

Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults

21 January 2018

1 reference

Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study

21 January 2018

1 reference

Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults

21 January 2018

1 reference

Glycation products as markers and predictors of the progression of diabetic complications

21 January 2018

1 reference

Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic review

21 January 2018

1 reference

Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury

21 January 2018

1 reference

Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes.

21 January 2018

1 reference

Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.

21 January 2018

1 reference

Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis

21 January 2018

1 reference

Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.

21 January 2018

1 reference

Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes

21 January 2018

1 reference

Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease.

21 January 2018

1 reference

RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases

21 January 2018

1 reference

Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts

21 January 2018

1 reference

Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy

21 January 2018

1 reference

Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.

21 January 2018

1 reference

Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process

21 January 2018

1 reference

PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease

21 January 2018

1 reference

Naturally occurring inhibitors against the formation of advanced glycation end-products

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/BIOF.1018

1 reference

26 August 2017

1 reference